ISBN: Outcomes No of Participants (studies) Follow up Quality of the evidence (GRADE) Relative effect Anticipated absolute effects Risk with Placebo Risk difference with Oral iron (95% CI) inconsistency Improvement in NYHA class Data on improvement in NYHA has only been extracted where quality of life data is not reported in a trial. VERY LOWa, b, c due to risk of bias, indirectness, imprecision Moderate (from 27 fewer to 1000 more) Permanent study drug discontinuation LOW b due to imprecision (from 78 fewer to 107 more) Adverse events (not described) 225 VERY LOWa, b, c due to risk of bias, indirectness, imprecision (from 146 fewer to 99 more) Serious adverse events (not described) VERY LOWa, b, c due to risk of bias, indirectness, imprecision (from 44 fewer to 136 more) Change in peak VO2 ml/kg/min 225 LOW a,d due to risk of bias - The median change in peak VO2 in the placebo group was ml/kg/min The median change in peak VO2 in the oral iron group was Change in 6-minute walk test distance (m) LOWa,d due to risk of bias - The median walk test distance in The median 6 minute walk test distance in the oral iron group was Treating Heart Failure Chronic Heart Failure NICE 2018. All rights reserved. Subject to Notice of rights. 